Intravitreal docosahexaenoic acid in a rabbit model: preclinical safety assessment

dc.contributor.authorDolz-Marco, Rosa
dc.contributor.authorGallego Pinazo, Roberto
dc.contributor.authorPinazo Durán, María Dolores
dc.contributor.authorPons-Vazquez, Sheila
dc.contributor.authorDomingo i Pedrol, Joan Carles
dc.contributor.authorDíaz Llopis, Manuel
dc.date.accessioned2015-04-10T14:35:34Z
dc.date.available2015-04-10T14:35:34Z
dc.date.issued2014-05-08
dc.date.updated2015-04-10T14:35:34Z
dc.description.abstractPurpose The purpose of the present study was to evaluate the retinal toxicity of a single dose of intravitreal docosahexaenoic acid (DHA) in rabbit eyes over a short-term period. Methods Sixteen New Zealand albino rabbits were selected for this pre-clinical study. Six concentrations of DHA (Brudy Laboratories, Barcelona, Spain) were prepared: 10 mg/50 µl, 5 mg/50 µl, 2'5 mg/50 µl, 50 µg/50 µl, 25 µg/50 µl, and 5 µg/50 µl. Each concentration was injected intravitreally in the right eye of two rabbits. As a control, the vehicle solution was injected in one eye of four animals. Retinal safety was studied by slit-lamp examination, and electroretinography. All the rabbits were euthanized one week after the intravitreal injection of DHA and the eyeballs were processed to morphologic and morphometric histological examination by light microscopy. At the same time aqueous and vitreous humor samples were taken to quantify the concentration of omega-3 acids by gas chromatography. Statistical analysis was performed by SPSS 21.0. Results Slit-lamp examination revealed an important inflammatory reaction on the anterior chamber of the rabbits injected with the higher concentrations of DHA (10 mg/50 µl, 5 mg/50 µl, 2'5 mg/50 µ) Lower concentrations showed no inflammation. Electroretinography and histological studies showed no significant difference between control and DHA-injected groups except for the group injected with 50 µg/50 µl. Conclusions Our results indicate that administration of intravitreal DHA is safe in the albino rabbit model up to the maximum tolerated dose of 25 µg/50 µl. Further studies should be performed in order to evaluate the effect of intravitreal injection of DHA as a treatment, alone or in combination, of different retinal diseases.
dc.format.extent8 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec650695
dc.identifier.issn1932-6203
dc.identifier.pmid24809445
dc.identifier.urihttps://hdl.handle.net/2445/64893
dc.language.isoeng
dc.publisherPublic Library of Science (PLoS)
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0096872
dc.relation.ispartofPLoS One, 2014, vol. 9, num. 5, p. e96872-e96872
dc.relation.urihttp://dx.doi.org/10.1371/journal.pone.0096872
dc.rightscc-by (c) Dolz-Marco, Rosa et al., 2014
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Bioquímica i Biomedicina Molecular)
dc.subject.classificationRetina
dc.subject.classificationExperimentació animal
dc.subject.classificationDegeneració (Patologia)
dc.subject.classificationÀcids grassos
dc.subject.classificationRatolins
dc.subject.otherRetina
dc.subject.otherAnimal experimentation
dc.subject.otherDegeneration (Pathology)
dc.subject.otherFatty acids
dc.subject.otherMice
dc.titleIntravitreal docosahexaenoic acid in a rabbit model: preclinical safety assessment
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
650695.pdf
Mida:
305.26 KB
Format:
Adobe Portable Document Format